ClinicalTrials.gov

History of Changes for Study: NCT03853018
Effectiveness of Activity Trackers to Reduce Sedentary Behaviour in Sedentary Adults (CWATLDP)
Latest version (submitted June 9, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 21, 2019 None (earliest Version on record)
2 February 11, 2020 Study Status
3 June 9, 2021 Recruitment Status, Study Status, Contacts/Locations and Study Design
Comparison Format:

Scroll up to access the controls

Study NCT03853018
Submitted Date:  February 21, 2019 (v1)

Open or close this module Study Identification
Unique Protocol ID: CWATLDP-001
Brief Title: Effectiveness of Activity Trackers to Reduce Sedentary Behaviour in Sedentary Adults (CWATLDP)
Official Title: The Effectiveness of Consumer Wearable Activity Trackers to Reduce Sedentary Behaviour and Improve Health-related Outcomes in Sedentary Adults
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2019
Overall Status: Recruiting
Study Start: November 15, 2018
Primary Completion: November 2019 [Anticipated]
Study Completion: January 2020 [Anticipated]
First Submitted: November 15, 2018
First Submitted that
Met QC Criteria:
February 21, 2019
First Posted: February 25, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
February 21, 2019
Last Update Posted: February 25, 2019 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Hasselt University
Responsible Party: Principal Investigator
Investigator: Bert Op't Eijnde
Official Title: Principal Investigator
Affiliation: Hasselt University
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This study evaluates the effectiveness of consumer wearable activity trackers to reduce sedentary behaviour and the impact on cardiometabolic health.
Detailed Description:

Chronic non-communicable diseases (NCDs), including cardiovascular diseases, cancer, chronic respiratory diseases and diabetes, are an important public health concern worldwide. Physical inactivity is one of the major contributing factors which is highly correlated with the prevalence of NCDs. On the other hand, it is well known that increased physical activity has significant health benefits and is associated with the prevention and delayed onset of many NCDs. Given the important role of physical activity in the prevention and management of NCDs it is thus important to promote physical activity. Hence, to date a multitude of physical activity recommendations and many supervised training interventions and rehabilitation programs are available to encourage physical activity in the global population. Despite this, a recent report from the World Health Organization (WHO) indicates that 23% of the adult and 80% of the adolescent population remains physically inactive. Here, long-term compliance to adequate physical activity and a healthy life style appears to be one of the main barriers explaining this discrepancy. Consequently, any strategy that improves long term adherence to adequate daily physical activity and a healthy life style, especially in an NCD population, is worthwhile investigating. In this respect and following the recent use of accelerometer-based remote monitoring of physical activity in chronic disease patients, consumer wearable activity trackers may be such a strategy. So far, consumer wearable activity trackers have been investigated mainly in the sports community. Here CWATs are used for self-monitoring and providing continuous sport performance and health related information to athletes and coaches. Interestingly, the self-management, motivational and goal setting properties of these commercially available devices may also help patients with NCDs to engage in long-term physical activity under free-living conditions in a home-based setting. Despite the widespread use of these wearables their feasibility and effectiveness on physical activity (compliance) and generic health-related outcomes, including weight, body mass index (BMI), systemic blood pressure and glycemic index, especially in patients with NCDs is not fully clear.

Therefore, the aim of this study is to investigate the effectiveness of CWATs to promote physical activity levels and cardiometabolic health in sedentary adults. A better understanding to what extent CWATs can actually improve physical activity (compliance) and health outcomes is important to increase the effectiveness and quality of health care in chronic disease populations.

Open or close this module Conditions
Conditions: Sedentary Lifestyle
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Supportive Care
Study Phase: Not Applicable
Interventional Study Model: Parallel Assignment
Number of Arms: 3
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 90 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
No Intervention: Control group
The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
Experimental: CWAT intervention group
The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
Device: CWAT intervention
Participant in the intervention group will wear an activity tracker for 12 weeks.
Experimental: CWAT + motivation intervention group
Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
Device: CWAT intervention
Participant in the intervention group will wear an activity tracker for 12 weeks.
Device: CWAT + motivation intervention group
Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Steps per day
[ Time Frame: Baseline ]

Physical activity will be quantified using the activPAL3™ activity monitor.
2. sitting time
[ Time Frame: baseline ]

sedentary behaviour will be quantified using the activPAL3™ activity monitor.
3. Steps per day
[ Time Frame: week 12 ]

Physical activity will be quantified using the activPAL3™ activity monitor.
4. sitting time
[ Time Frame: week 12 ]

sedentary behaviour will be quantified using the activPAL3™ activity monitor.
Secondary Outcome Measures:
1. body weight
[ Time Frame: baseline ]

Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
2. body weight
[ Time Frame: week 12 ]

Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
3. Height
[ Time Frame: baseline ]

Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot
4. Height
[ Time Frame: week 12 ]

Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot
5. DEXA (Dual Energy X-Ray)
[ Time Frame: baseline ]

body fat mass and lean tissue mass using Dual Energy X-ray Absorptiometry
6. DEXA (Dual Energy X-Ray)
[ Time Frame: week 12 ]

body fat mass and lean tissue mass using Dual Energy X-ray Absorptiometry
7. Concentration of glucose
[ Time Frame: baseline ]

Blood analysis
8. Concentration of glucose
[ Time Frame: week 12 ]

Blood analysis
9. Concentration of Insuline
[ Time Frame: baseline ]

Blood analysis
10. Concentration of Insuline
[ Time Frame: week 12 ]

Blood analysis
11. Concentration of total cholesterol
[ Time Frame: baseline ]

Blood analysis
12. total cholesterol
[ Time Frame: week 12 ]

Blood analysis
13. Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
[ Time Frame: baseline ]

Blood analysis
14. Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
[ Time Frame: week 12 ]

Blood analysis
15. Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
[ Time Frame: baseline ]

Blood analysis
16. Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
[ Time Frame: week 12 ]

Blood analysis
17. Concentration of triglyceride
[ Time Frame: baseline ]

Blood analysis
18. Concentration of triglyceride
[ Time Frame: week 12 ]

Blood analysis
19. Concentration of glycated haemoglobin (HbA1c)
[ Time Frame: baseline ]

Blood analysis
20. Concentration of glycated haemoglobin (HbA1c)
[ Time Frame: week 12 ]

Blood analysis
21. Concentration of uric acid
[ Time Frame: baseline ]

Blood analysis
22. Concentration of uric acid
[ Time Frame: week 12 ]

Blood analysis
23. Concentration of interleukin 6 (IL-6),
[ Time Frame: baseline ]

Blood analysis
24. Concentration of interleukin 6 (IL-6),
[ Time Frame: week 12 ]

Blood analysis
25. Concentration of tumor necrosis factor-alpha (TNF-α),
[ Time Frame: baseline ]

Blood analysis
26. Concentration of tumor necrosis factor-alpha (TNF-α),
[ Time Frame: week 12 ]

Blood analysis
27. Concentration of C-reactive protein (CRP)
[ Time Frame: baseline ]

Blood analysis
28. Concentration of C-reactive protein (CRP)
[ Time Frame: week 12 ]

Blood analysis
29. Concentration of serum amyloid A (SAA)
[ Time Frame: baseline ]

Blood analysis
30. Concentration of serum amyloid A (SAA)
[ Time Frame: week 12 ]

Blood analysis
31. Concentration of soluble vascular cell adhesion molecule-1 (sVCAM-1),
[ Time Frame: baseline ]

Blood analysis
32. Concentration of soluble vascular cell adhesion molecule-1 (sVCAM-1),
[ Time Frame: week 12 ]

Blood analysis
33. Concentration of soluble intercellular adhesion molecule 1 (sICAM-1)
[ Time Frame: baseline ]

Blood analysis
34. Concentration of soluble intercellular adhesion molecule 1 (sICAM-1)
[ Time Frame: week 12 ]

Blood analysis
35. Concentration of soluble E-selectin (sE-selectin).
[ Time Frame: baseline ]

Blood analysis
36. Concentration of soluble E-selectin (sE-selectin).
[ Time Frame: week 12 ]

Blood analysis
37. Vascular endothelial function
[ Time Frame: baseline ]

Endothelial function will be assessed by non-invasive peripheral arterial tonometry using the EndoPAT™ 2000 device
38. Vascular endothelial function
[ Time Frame: week 12 ]

Endothelial function will be assessed by non-invasive peripheral arterial tonometry using the EndoPAT™ 2000 device
39. Homeostatic model assessment for insulin resistance (HOMA-IR)
[ Time Frame: baseline ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the homeostatic model assessment for insulin resistance (HOMA-IR). The HOMA-IR is calculated from the fasting insulin and glucose concentration.sensitivity and beta cell function. The following parameters are calculated: homeostatic model assessment for insulin resistance, whole-body insulin sensitivity index, insulinogenic index and the area under the curve for glucose and insulin.
40. Homeostatic model assessment for insulin resistance (HOMA-IR)
[ Time Frame: week 12 ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the homeostatic model assessment for insulin resistance (HOMA-IR). The HOMA-IR is calculated from the fasting insulin and glucose concentration.sensitivity and beta cell function. The following parameters are calculated: homeostatic model assessment for insulin resistance, whole-body insulin sensitivity index, insulinogenic index and the area under the curve for glucose and insulin.
41. Whole-body insulin sensitivity index (ISI)
[ Time Frame: baseline ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the whole-body insulin sensitivity index (ISI). The ISI is calculated from both insulin and glucose concentrations.
42. Whole-body insulin sensitivity index (ISI)
[ Time Frame: week 12 ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the whole-body insulin sensitivity index (ISI). The ISI is calculated from both insulin and glucose concentrations.
43. Area under the curve of insulin concentrations
[ Time Frame: baseline ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of insulin concentrations.
44. Area under the curve of insulin concentrations
[ Time Frame: week 12 ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of insulin concentrations.
45. Area under the curve of glucose concentrations
[ Time Frame: baseline ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of glucose concentrations.
46. Area under the curve of glucose concentrations
[ Time Frame: week 12 ]

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of glucose concentrations.
47. Insulinogenic index
[ Time Frame: baseline ]

An oral glucose tolerance test will be performed for assessment of beta cell function by calculation of the insulinogenic index. The insulinogenic index is calculated from both insulin and glucose concentrations.
48. Insulinogenic index
[ Time Frame: week 12 ]

An oral glucose tolerance test will be performed for assessment of beta cell function by calculation of the insulinogenic index. The insulinogenic index is calculated from both insulin and glucose concentrations.
49. Cardiac autonomic function
[ Time Frame: baseline ]

Cardiac autonomic function will be operationalized as heart rate variability by means of continuous beat-to-beat heart rate signal measurements. time domain and frequency domain analysis of the R-R intervals will be performed
50. Cardiac autonomic function
[ Time Frame: week 12 ]

Cardiac autonomic function will be operationalized as heart rate variability by means of continuous beat-to-beat heart rate signal measurements. time domain and frequency domain analysis of the R-R intervals will be performed
51. Systolic and Diastolic Blood pressure
[ Time Frame: baseline ]

Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer
52. Systolic and Diastolic Blood pressure
[ Time Frame: week 12 ]

Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer
53. Oxygen uptake (VO2)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VO2 is collected breath-by-breath and averaged every ten seconds.
54. Oxygen uptake (VO2)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VO2 is collected breath-by-breath and averaged every ten seconds.
55. Carbon dioxide output (VCO2)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VCO2 is collected breath-by-breath and averaged every ten seconds.
56. Carbon dioxide output (VCO2)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VCO2 is collected breath-by-breath and averaged every ten seconds.
57. Minute ventilation (VE)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE is collected breath-by-breath and averaged every ten seconds.
58. Minute ventilation (VE)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE is collected breath-by-breath and averaged every ten seconds.
59. Equivalents for oxygen uptake (VE/VO2)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE/VO2 is collected breath-by-breath and averaged every ten seconds.
60. Equivalents for oxygen uptake (VE/VO2)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE/VO2 is collected breath-by-breath and averaged every ten seconds.
61. Equivalents for carbon dioxide production (VE/VCO2)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE/VCO2 is collected breath-by-breath and averaged every ten seconds.
62. Equivalents for carbon dioxide production (VE/VCO2)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE/VCO2 is collected breath-by-breath and averaged every ten seconds.
63. Tidal volume (Vt)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis Vt is collected breath-by-breath and averaged every ten seconds.
64. Tidal volume (Vt)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis Vt is collected breath-by-breath and averaged every ten seconds.
65. Breathing frequency (BF)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis BF is collected breath-by-breath and averaged every ten seconds.
66. Breathing frequency (BF)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis BF is collected breath-by-breath and averaged every ten seconds.
67. Respiratory gas exchange ratio (RER)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis RER is collected breath-by-breath and averaged every ten seconds.
68. Respiratory gas exchange ratio (RER)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis RER is collected breath-by-breath and averaged every ten seconds.
69. Heart rate (HR)
[ Time Frame: baseline ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of a heart rate monitor the HR is measured and averaged every ten seconds.
70. Heart rate (HR)
[ Time Frame: week 12 ]

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of a heart rate monitor the HR is measured and averaged every ten seconds.
71. A six-minute walk test
[ Time Frame: baseline ]

The covered distance is measured during a six-minute walk test.
72. A six-minute walk test
[ Time Frame: week 12 ]

The covered distance is measured during a six-minute walk test.
73. Relative autonomy index
[ Time Frame: baseline ]

Individual motives for physical activity are assessed using the Behavioural Regulation and Exercise Questionnaire version 2 (BREQ-2).
74. Relative autonomy index
[ Time Frame: week 12 ]

Individual motives for physical activity are assessed using the Behavioural Regulation and Exercise Questionnaire version 2 (BREQ-2).
75. Total calorie intake
[ Time Frame: baseline ]

Participants will record all food and beverages consumed over seven consecutive days and from this the total calorie intake is calculated.
76. Total calorie intake
[ Time Frame: week 12 ]

Participants will record all food and beverages consumed over seven consecutive days and from this the total calorie intake is calculated.
77. Macronutrient content
[ Time Frame: baseline ]

Participants will record all food and beverages consumed over seven consecutive days and from this the macronutrient content is calculated.
78. Macronutrient content
[ Time Frame: week 12 ]

Participants will record all food and beverages consumed over seven consecutive days and from this the macronutrient content is calculated.
Open or close this module Eligibility
Minimum Age: 40 Years
Maximum Age: 75 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  • Sedentary adults
  • 40-75 years,
  • <7500steps/day,
  • sitting time of >10h/day,
  • BMI 23-30 kg/m2,
  • body fat percentage: male: 18-25%, female: 25-35%
  • HbA1c < 6.0%

Exclusion Criteria:

  • pregnancy,
  • regularly (>150 min per week during the last four months) engaged in moderate-to-vigorous intensity exercise,
  • any known contradiction for physical activity,
  • systolic blood pressure >160mmHg,
  • diastolic blood pressure >100mmHg
  • more than 20 alcohol consumptions per week,
  • plans to follow a weight reduction program with the aid of an energy restriction diet or a physical intervention program during the study period,
  • participants diagnosed with any known chronic disease.
Open or close this module Contacts/Locations
Central Contact Person: Bert Op 't Eijnde, prof.dr.
Telephone: +32 11 29 21 21
Email: bert.opteijnde@uhasselt.be
Central Contact Backup: Wouter Franssen, drs.
Telephone: +32 11 29 21 29
Email: wouter.franssen@uhasselt.be
Study Officials: Bert Op 't Eijnde, prof. dr.
Study Chair
Hasselt University
Wouter Franssen, drs.
Principal Investigator
Hasselt University
Locations: Belgium, Limburg
Hasselt University
[Recruiting]
Diepenbeek, Limburg, Belgium, 3590
Contact:Contact: Wouter Franssen, MSc +3211292129 wouter.franssen@uhasselt.be
Contact:Contact: Bert Op 't Eijnde, Prof. +3211292121 bert.opteijnde@uhasselt.be
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services